Originally developed in Australia in the 1990s, it was designed to harness the fat-burning properties of growth hormone without triggering its broader hormonal effects
In 2025 the FDA expanded Wegovy's indication to include adults with MASH and moderate to advanced liver fibrosis, on the strength of the ESSENCE Phase 3 trial (FDA Drugs)
Slight irritation is normal, and temporary
Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized
Authors' contributions: JS and DF participated in the conception and design of the review, revised the whole manuscript, and read and approved the final manuscript
And if somebody already is using them for diabetes or so, and in addition, they get a benefit for alcoholism, thats great, too.